PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)

Latest AI Signal: SELL
Status: EXPIRED
Days Old: 23

Confidence: 75.00%

Date: 28-04-2026

Price: $0.190

Last Price: $0.160

Post-Signal Low Price: $0.160

Latest  PARADIGM BIOPHARMACEUTICALS LIMITED(PAR)   News

25 May 2023, 11:10 AM

Hope for knee osteoarthritis sufferers with advent of global clinical trial.

Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (P

11 Apr 2023, 07:00 PM

Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up

Paradigm Biopharmaceuticals Top-line phase 2 trial data shows disease modifying potential and pain reduction MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:PAR) says analysis of six-month trial data shows injectable pentosan polysulfate so

05 Oct 2022, 02:08 AM

Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial

KEY HIGHLIGHTS Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical trial (n=61). Several osteoarthritis (OA) biomarkers analysed were observed to favourably change over time in patients treated with injectable P

12 Aug 2022, 10:00 PM

MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases

KEY HIGHLIGHTS Paradigm has been invited to present results from the mucopolysaccharidosis (MPS) program, with an oral presentation at the XVII International Conference on Lysosomal Diseases (ICLD 2023), to be held in Sydney, Australia, February 20-21, 2023. Dr Drago Bratkovic, Head of the Metaboli

15 Jul 2022, 04:29 AM

Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

Key Highlights Paradigm as an NFL Alumni Health corporate member has entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA) and potential clinical trial participation. NFL Alumni Health is a wholly owned subsidiary of NFL Alumni offering informational resources,

Sell Confidence High

AI Confidence - 75.00 % model confidence

Business Overview

Paradigm Biopharmaceuticals Limited is a clinical-stage biopharmaceutical company focused on developing novel treatments for osteoarthritis and other musculoskeletal conditions. The company is positioned in the niche regenerative medicine market, leveraging its proprietary Pentosan Polysulfate Sodium (PPS) platform to target unmet medical needs with potential disease-modifying therapies.

Financial Analysis

Cash Flow	Weak
Debt	Moderate
Profitability	Weak
Revenue Trend	Downtrend

Technical Analysis

Trend	Bearish
Momentum	Weak
RSI Signal	Oversold
Support Level	$ 0.18
Resistance Level	$ 0.22

Valuation

Valuation - Overvalued

The current market price appears elevated relative to the company's early-stage pipeline and lack of revenue, reflecting speculative investor sentiment rather than fundamental value.

Catalysts

• Upcoming clinical trial results for lead osteoarthritis drug candidate.

• Regulatory feedback or approval milestones.

• Partnership or licensing deals to enhance pipeline value.

Recommendation

Action - Sell

Timeframe - Short Term

Given the weak financials, high development risk, and bearish technical signals, the stock is likely to face downward pressure in the near term. Investors should consider reducing exposure until clearer clinical progress or valuation support emerges.